APPENDIX A:

PENDING CLAIMS AS OF PRELIMINARY AMENDMENT

- 18. (Amended) A method of screening for a modulator of calpain function comprising:
 - a) obtaining a calpain polypeptide;
 - b) determining a standard activity profile of the calpain polypeptide;
 - c) contacting the calpain polypeptide with a putative modulator; and
 - d) assaying for a change in the standard activity profile.
- 19. The method of claim 18, wherein the calpain polypeptide is a calpain 10 polypeptide.
- 20. The method of claim 18, wherein obtaining the calpain polypeptide comprises expressing the polypeptide in a host cell.
- 21. The method of claim 20, wherein the calpain polypeptide is isolated away from the host cell prior to contacting the calpain polypeptide with the putative modulator.
- 50. The method of claim 19, wherein the standard activity profile of the calpain 10 polypeptide is determined by measuring the binding of the calpain 10 polypeptide to a synthetic substrate.
- 51. The method of claim 50, wherein the synthetic substrate is Suc-Leu-Tyr-AMC.
- 52. A method of screening for a modulator of calpain function comprising:
 - a) obtaining an calpain polypeptide;
 - b) contacting the calpain polypeptide with a putative modulator; and
 - c) assaying for modulation of calpain function by the putative modulator.
- 53. The method of claim 52, wherein the calpain polypeptide is a calpain 10 polypeptide.

- 54. The method of claim 53, wherein the calpain 10 polypeptide has a sequence comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:18.
- 55. The method of claim 52, further comprising determining a standard activity profile of the calpain polypeptide.
- 56. The method of claim 55, wherein the standard activity profile of the calpain 10 polypeptide is determined by measuring the binding of the calpain 10 polypeptide to a synthetic substrate.
- 57. The method of claim 56, wherein the synthetic substrate is Suc-Leu-Tyr-AMC.
- 58. The method of claim 56, wherein assaying for modulation of calpain function comprises assaying for a change in the standard activity profile.
- 59. The method of claim 52, wherein obtaining the calpain polypeptide comprises expressing the polypeptide in a host cell.
- 60. The method of claim 59, wherein the calpain polypeptide is isolated away from the host cell prior to contacting the calpain polypeptide with the putative modulator.
- 61. The method of claim 52, wherein obtaining the calpain polypeptide comprises obtaining a cell containing the polypeptide.
- 62. The method of claim 61, wherein the cell is a pancreatic cell, a muscle cell, an adipose cell, or a liver cell.
- 63. The method of claim 62, wherein the cell is a pancreatic cell.

- 64. The method of claim 63, wherein the pancreatic cell is comprised in an isolated pancreatic islet.
- 65. The method of claim 63, wherein the cell is a β -cell.
- 66. A method of screening for a modulator of calpain function comprising:
 - a) obtaining an calpain-encoding nucleic acid segment;
 - b) determining a standard transcription and translation activity of the calpain nucleic acid sequence;
 - c) contacting the calpain-encoding nucleic acid segment with a putative modulator;
 - d) maintaining the nucleic acid segment and putative modulator under conditions that normally allow for calpain transcription and translation; and
 - e) assaying for a change in the transcription and translation activity.
- 67. The method of claim 66, wherein the calpain-encoding nucleic acid segment encodes calpain 10.
- 68. A calpain modulator prepared by a process comprising screening for a modulator of calpain function comprising:
 - a) obtaining an calpain polypeptide;
 - b) determining a standard activity profile of the calpain polypeptide;
 - c) contacting the calpain polypeptide with a putative modulator; and
 - d) assaying for a change in the standard activity profile.
- 69. The modulator of claim 68, wherein obtaining the calpain polypeptide comprises expressing the polypeptide in a host cell.
- 70. The modulator of claim 68, wherein the calpain polypeptide is a calpain 10 polypeptide.
- 71. The modulator of claim 69, wherein the calpain polypeptide is isolated away from the host cell prior to contacting the calpain polypeptide with the putative modulator.

- 72. The modulator of claim 68, wherein the modulator of calpain function is a modulator of a calpain polypeptide.
- 73. The modulator of claim 72, wherein the calpain polypeptide is a calpain 10 polypeptide.
- 74. The modulator of claim 73, wherein the calpain 10 polypeptide has a sequence comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:18.
- 75. The modulator of claim 68, wherein the modulator of calpain function is an agonist or antagonist of a calpain polypeptide.
- 76. The modulator of claim 75, wherein the modulator of calpain function is an inhibitor of a calpain polypeptide.
- 77. The modulator of claim 76, wherein the modulator inhibits calpain I and/or calpain II.
- 78. The modulator of claim 76, wherein the modulator is calpeptin.
- 79. The modulator of claim 76, wherein the modulator is calpain inhibitor 2 (ALLM).
- 80. The modulator of claim 76, wherein the modulator of calpain function is a protease inhibitor.
- 81. The modulator of claim 80, wherein the protease inhibitor is a thiol protease inhibitor.
- 82. The modulator of claim 81, wherein the thiol protease inhibitor is E-64-d.
- 83. The modulator of claim 68, further defined as a method comprising inhibiting calpain activity in a β -cell with a modulator of calpain function.

- 84. The modulator of claim 68, further defined as a method comprising stimulating calpain activity in a muscle cell or fat cell with a modulator of calpain function.
- 85. The modulator of claim 68, further defined as a method comprising stimulating calpain activity in a fat call or muscle cell with a modulator of calpain function and inhibiting calpain activity in a β -cell with a modulator of calpain function.
- 86. A calpain modulator prepared by a process comprising screening for a modulator of calpain function comprising:
 - a) obtaining a calpain-encoding nucleic acid segment;
 - b) determining a standard transcription and translation activity of the calpain nucleic acid sequence;
 - c) contacting the calpain-encoding nucleic acid segment with a putative modulator;
 - d) maintaining the nucleic acid segment and putative modulator under conditions that normally allow for calpain transcription and translation; and
 - e) assaying for a change in the transcription and translation activity.
- 87. The method of claim 86, wherein the calpain-encoding nucleic acid segment encodes calpain 10.
- 88. A method of treating diabetes by modulating the function of one or more calpains in at least one of a β -cell, muscle cell, or fat cell with a modulator of calpain function, wherein the modulator is prepared by a process comprising screening for a modulator of calpain function comprising:
 - a) obtaining a calpain-encoding nucleic acid segment;
 - b) determining a standard transcription and translation activity of the calpain nucleic acid sequence;
 - c) contacting the calpain-encoding nucleic acid segment with a putative modulator;
 - d) maintaining the nucleic acid segment and putative modulator under conditions that normally allow for calpain transcription and translation; and

- e) assaying for a change in the transcription and translation activity.
- 89. The method of claim 88, wherein the calpain-encoding nucleic acid segment encodes calpain 10.
- 90. A method of treating diabetes by modulating the function of one or more calpains in at least one of a β -cell, muscle cell, or fat cell with a modulator of calpain function, wherein the modulator is prepared by a process comprising screening for modulators of calpain function comprising:
 - a) obtaining an calpain polypeptide;
 - b) determining a standard activity profile of the calpain polypeptide;
 - c) contacting the calpain polypeptide with a putative modulator; and
 - d) assaying for a change in the standard activity profile.
- 91. The method of claim 90, wherein the modulator of calpain function is a modulator of a calpain polypeptide.
- 92. The method of claim 91, wherein the calpain polypeptide is a calpain 10 polypeptide.
- 93. The method of claim 92, wherein the calpain 10 polypeptide has a sequence comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, or SEQ ID NO:18.
- 94. The method of claim 91, wherein the modulator of calpain function is an agonist or antagonist of a calpain polypeptide.
- 95. The method of claim 91, wherein the modulator of calpain function is an inhibitor of a calpain polypeptide.
- 96. The method of claim 95, wherein the modulator inhibits calpain I and/or calpain II.

- 97. The method of claim 95, wherein the modulator is calpeptin.
- 98. The method of claim 95, wherein the modulator is calpain inhibitor 2 (ALLM).
- 99. The method of claim 95, wherein the modulator of calpain function is a protease inhibitor.
- 100. The method of claim 99, wherein the protease inhibitor is a thiol protease inhibitor.
- 101. The method of claim 100, wherein the thiol protease inhibitor is E-64-d.
- 102. The method of claim 90, further defined as a method comprising inhibiting calpain activity in a β -cell with a modulator of calpain function.
- 103. The method of claim 90, further defined as a method comprising stimulating calpain activity in a muscle cell or fat cell with a modulator of calpain function.
- 104. The method of claim 90, further defined as a method comprising stimulating calpain activity in a fat call or muscle cell with a modulator of calpain function and inhibiting calpain activity in a β -cell with a modulator of calpain function.
- 105. The method of claim 90, wherein the standard activity profile of the calpain 10 polypeptide is determined by measuring the binding of the calpain 10 polypeptide to a synthetic substrate.
- 106. The method of claim 105, wherein the synthetic substrate is Suc-Leu-Tyr-AMC.
- 107. The method of claim 105, wherein assaying for modulation of calpain function comprises assaying for a change in the standard activity profile.

- 108. The method of claim 90, wherein obtaining the calpain polypeptide comprises expressing the polypeptide in a host cell.
- 109. The method of claim 108, wherein the calpain polypeptide is isolated away from the host cell prior to contacting the calpain polypeptide with the putative modulator.
- 110. The method of claim 90, wherein obtaining the calpain polypeptide comprises obtaining a cell containing the polypeptide.
- 111. The method of claim 110, wherein the cell is a pancreatic cell, a muscle cell, an adipose cell, or a liver cell.
- 112. The method of claim 111, wherein the cell is a pancreatic cell.
- 113. The method of claim 112, wherein the pancreatic cell is comprised in an isolated pancreatic islet.
- 114. The method of claim 112, wherein the cell is a β -cell.